4P-Pharma Announces Total Capital of €15 Million Successfully Secured in Second Closing

LILLE, France & PARIS--(BUSINESS WIRE)--Apr 29, 2024--

4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of €15 million in its second closing with participation from private investors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424933193/en/

(Graphic: Business Wire)

With this funding, 4P-Pharma’s shareholders renew their confidence in the company’s drug regeneration model for untreated serious diseases. They welcome the entry of Phase 2 clinical development of the two first 4P-Pharma’s SPVs, underlying the robust potential of the company’s business model.

Revital Rattenbach , CEO of 4P-Pharma: “As CEO of 4P-Pharma, I am pleased with the renewed trust of our investors placed in our scientific and development approach year after year. This financial endorsement underscores our significant progress over the past decade. It attests to the strength of our model for delivering first-in-class treatments for people suffering from untreated serious diseases.”

This additional shareholders’ financial backing is a boost that will allow 4P-Pharma to deploy its drug regeneration model triggered by an unrevealed match between established MOA with unexplored targeting of disease biology, paving the way for developing first-in-class therapies.

This cashflow reserve ensures financial stability and operational agility to engage actively external growth opportunities through M&A and licensing-in and accelerate 4P-Pharma’s startup studio model for building a balanced pipeline towards the commercial stage.

Revital Rattenbach concludes: “After a decade of existence, 4P-Pharma is opening a novel turning point of its growth. This successful capital-secure will enable us to push forward our patient-centric vision transforming science into success stories for the best for the patients and the whole medical community.”

About 4P-Pharma

Founded in 2014, 4P-Pharma is a clinical-stage biotechnology company based in Lille dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Our goal is to bring first-class medicines to patients rapidly. 4P-Pharma leverages drug candidates with reduced development times, partly thanks to regulatory opportunities (emergency use or conditional market authorization) with strong intellectual property. The company is headquartered in Lille and Paris and has over 20 employees.

Site internet : https://4p-pharma.com/fr

LinkedIn: https://fr.linkedin.com/company/4p-pharma

X: https://twitter.com/4P_Pharma/

The only version of the 4P-Pharma press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.

View source version on businesswire.com:https://www.businesswire.com/news/home/20240424933193/en/

CONTACT: Press Contacts

Financial Communication and Investor Relations

Jérôme Vailland – Chief Financial Officer

jerome.vailland@4p-pharma.comCommunication – Press Relations

Emmanuel Dadjé - Communication Manager

Emmanuel.dadje@4P-Pharma.com

Tel : +33 6 30 06 12 13

KEYWORD: FRANCE EUROPE

INDUSTRY KEYWORD: RESEARCH MANAGED CARE PROFESSIONAL SERVICES PHARMACEUTICAL FITNESS & NUTRITION CLINICAL TRIALS SCIENCE BIOTECHNOLOGY FINANCE OTHER SCIENCE HEALTH DIABETES

SOURCE: 4P-Pharma

PUB: 04/29/2024 12:40 AM/DISC: 04/29/2024 12:41 AM

http://www.businesswire.com/news/home/20240424933193/en